<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01589185</url>
  </required_header>
  <id_info>
    <org_study_id>KBSA301-001</org_study_id>
    <nct_id>NCT01589185</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetics and Efficacy of KBSA301 in Severe Pneumonia (S. Aureus)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, Efficacy and Pharmacodynamics of KBSA301 in Severe Pneumonia (S. Aureus)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aridis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aridis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to assess the safety, tolerability, pharmacokinetics,
      pharmacodynamics and clinical outcome of patients who have severe pneumonia caused by
      Staphylococcus aureus (S. aureus) after a single intravenous administration of KBSA301 in
      addition of standard of care antibiotic treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      S. aureus is a leading cause of bloodstream, skin, soft tissue, and lower respiratory tract
      infections worldwide. The frequencies of both nosocomial and community-acquired S. aureus
      infections have increased steadily over the years and the treatment of these infections has
      become more challenging due to the emergence of multi-drug resistant strains (e.g.
      methicillin-resistant Staphylococcus aureus).

      S. aureus has several virulence factors that contribute to the pathogenesis of the infection.
      Amongst them, alpha-toxin that is involved in the pathogenesis of pneumonia, as it leads to
      apoptosis and cell lysis, in particular lymphocytes, macrophages, alveolar epithelial cells,
      pulmonary endothelium, and thrombocytes.

      In spite of preventive measures for S. aureus infections and current medical treatment
      (mostly antibiotic therapy, alone or in combination), there is a clear unmet medical need in
      the clinic for additional treatment options. Passive immunotherapy with monoclonal antibodies
      may improve treatment options for severe and life-threatening infections like those caused by
      S. aureus.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>From drug administration up to 107 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) in plasma of KBSA301 after a single-dose intravenous administration</measure>
    <time_frame>Predose and 1, 2, 4, 12, 24, 48 hours after start of infusion, and on Days 8, 15, 29, 57, 85, and 107 post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) in plasma of KBSA301 after a single-dose intravenous administration</measure>
    <time_frame>Predose and 1, 2, 4, 12, 24, 48 hours after start of infusion, and on Days 8, 15, 29, 57, 85, and 107 post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life in plasma of KBSA301 after a single-dose intravenous administration</measure>
    <time_frame>Predose and 1, 2, 4, 12, 24, 48 hours after start of infusion, and on Days 8, 15, 29, 57, 85, and 107 post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of anti-drug-antibodies of KBSA301</measure>
    <time_frame>Pre-dose and on days 15, 29, 57, and 107 post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival (all-cause mortality within 28 days after treatment)</measure>
    <time_frame>Days 15, 28, 57 and at day 107</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in bacterial load from respiratory samples</measure>
    <time_frame>Predose and one additional sample obtained between Day 8 and Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Response of pneumonia: Cure</measure>
    <time_frame>Daily until Day 29</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Pneumonia Due to Staphylococcus Aureus</condition>
  <arm_group>
    <arm_group_label>KBSA301, a monoclonal antibody dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg/kg KBSA301</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KBSA301, a monoclonal antibody dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 mg/kg KBSA301</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KBSA301, a monoclonal antibody dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg/kg KBSA301</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KBSA301, a monoclonal antibody dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg/kg KBSA301</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KBSA301-placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KBSA301</intervention_name>
    <description>KBSA301 administered as a single intravenous infusion at dose 1, 2, 3 and 4.</description>
    <arm_group_label>KBSA301, a monoclonal antibody dose 1</arm_group_label>
    <arm_group_label>KBSA301, a monoclonal antibody dose 2</arm_group_label>
    <arm_group_label>KBSA301, a monoclonal antibody dose 3</arm_group_label>
    <arm_group_label>KBSA301, a monoclonal antibody dose 4</arm_group_label>
    <other_name>AR301</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered as a single intravenous infusion</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo KBSA301</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult male or female patients ≥ 18 years and ≤ 70 years of age

          -  Severe pneumonia caused by S. aureus (either methicillin-resistant or
             methicillin-sensitive) managed in an ICU

          -  APACHE II of ≤30 at the time of diagnosis

          -  Identification of S. aureus

          -  Written informed consent provided by the patient, the relatives or the designated
             trusted person and/or according to local guidelines

        Exclusion Criteria:

          -  Women of child bearing potential are excluded from the participation from the study
             unless they have a negative pregnancy test at baseline and during the course of the
             study. Postmenopausal women or females that have been surgically sterilized are
             allowed to participate.

          -  Hypersensitivity to excipients or to any prescribed medication

          -  Severe neutropenia, lymphoma or anticipated chemotherapy

          -  Patients who have long-term tracheostomy

          -  Current or recent investigational drug (within 30 days of enrollment, or 5 half-lives
             of the investigational compound, whichever is longer)

          -  Presence of meningitis, endocarditis, or osteomyelitis

          -  Acquired immune deficiency syndrome (AIDS) with cluster of differentiation 4 (CD4)
             count &lt;200 cells/ml

          -  Known bronchial obstruction or a history of post-obstructive pneumonia.

          -  Active primary lung cancer or another malignancy metastatic to the lungs

          -  Cystic fibrosis, known or suspected Pneumocystis jiroveci pneumonia, or known or
             suspected active tuberculosis

          -  Immunosuppressive therapy

          -  Liver function deficiency

          -  Moribund clinical condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre-François Laterre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université catholique de Louvain, Brussels, Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 83</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 81</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 80</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 11</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 16</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 41</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 40</name>
      <address>
        <city>Angouleme</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 32</name>
      <address>
        <city>Argenteuil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 34</name>
      <address>
        <city>Colombes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 36</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 35</name>
      <address>
        <city>La Roche Sur Yon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 31</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 39</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 37</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 38</name>
      <address>
        <city>Orleans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 33</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 51</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 52</name>
      <address>
        <city>Bellvitge</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2012</study_first_submitted>
  <study_first_submitted_qc>April 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2012</study_first_posted>
  <last_update_submitted>September 21, 2016</last_update_submitted>
  <last_update_submitted_qc>September 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pneumonia</keyword>
  <keyword>Monoclonal antibody</keyword>
  <keyword>Staphylococcus aureus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Staphylococcal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

